tbuckley/cabot-search huggingface dataset:
THE EDITORIAL MANAGEMENT OF THE JOURNAL.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alterations in the Release of Norepinephrine at the Vascular Neuroeffector Junction in Hypertension
Authors: T. Westfall
Journal: The Annual Review of Pharmacology and Toxicology (1985)

Due to the massive data sets available for drug candidates, modern drug discovery has advanced to the big data era. Central to this shift is the development of artificial intelligence approaches to implementing innovative modeling based on the dynamic, ...Read More
Incorrect Information in the Abstract
Authors: Martin Stangel, Iris-Katharina Penner, Bernd Kieseier
Journal: JAMA Neurology (2014)

Ajay K. Parsaik, MD; Balwinder Singh, MD; Rosebud O. Roberts, MBBCh; Shane Pankratz, PhD; Kelly K. Edwards, MS; Yonas E. Geda, MD, MSc; Hossein Gharib, MD; Bradley F. Boeve, MD; David S. Knopman, MD; Ronald C. Petersen, MD, PhD
Omission of Data and Errors in Meta-analysis
Authors: Carrie Colla, Valerie Lewis, Lee-Sien Kao, Ba James O'malley, Chiang-Hua Chang, Elliott Fisher, O Kao, O Lewis
Journal: JAMA Internal Medicine (2017)

Wan-Chuan Tsai, MD; Hon-Yen Wu, MD, PhD; Yu-Sen Peng, MD, PhD; Ju-Yeh Yang, MD, BSc; Hung-Yuan Chen, MD; Yen-Ling Chiu, MD, PhD; Shih-Ping Hsu, MD, PhD; Mei-Ju Ko, MD, PhD; Mei-Fen Pai, MD; Yu-Kang Tu, DDS, PhD; Kuan-Yu Hung, MD, PhD; Kuo-Liong Chien, MD, PhD
Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan
Authors: F. Agustoni, G. Fucà, G. Corrao, C. Vernieri, S. Cavalieri, A. Raimondi, G. Peverelli, M. Prisciandaro, P. Indelicato, K. Dotti, F. Morano, G.L.o. Russo, D. Signorelli, C. Proto, M. Vitali, M. Imbimbo, N. Zilembo, M. Garassino, F.G.M. De Braud, M. Platania
Journal: Annals of Oncology (2016)
MEDICAL MEMBER OF THE CANAL COMMISSION.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
Authors: J. Kolesar, J. Brahmer, J. Lee, P. Guaglianone, J. Patel, M. Keppen, M. Hidalgo, D. Carbone, J. Schiller
Journal: Journal of Clinical Oncology (2007)

7588 Background: Predictors of response and survival in patients (pts) who benefit from Erlotinib (Elb) remain controversial. The primary objective is to prospectively identify downstream markers of EGFR linked signaling pathways that are predictive of response. The secondary objectives are to estimate response rate (RR), disease control rate (dcr), time to progression (ttp), survival, and if a grade (gr) 2 rash is predictive of survival. Methods: Pts with advanced NSCLC (Stage IIIB with pleural effusion and IV, no prior systemic treatment, performance status 0–2, no symptomatic CNS metastasis, and adequate renal, hepatic and hematologic function) were accrued to this single arm study. Elb was taken orally once a day until disease progression or unacceptable toxicity. Starting at 150 mg per day, the dose was escalated by 25 mg once every 2 weeks until a gr 2 rash developed, other toxicities precluded escalation, or 250 mg dose reached. Paraffin- fixed tumor tissue was collected on pts for correlative studies including quantitative immunohistochemistry (IHC) for pMAPK. Results: Of 137 pts recruited, 118 were eligible and 57 pts had adequate tissue to do IHC. Dose escalation occurred in 60/118 pts, with 15 getting up to 250 mg. The RR, by RECIST criteria, was 7% (8/112, 1 CR) with dcr of 46% (51/112). Most pts went off trial because of progression of disease (69%). Median survival was 7.9 months (mo), and median ttp was 3.5 mo. Of the 134 pts evaluated for toxicity, 43 (32%), 66 (49%), and 13 (10%) had a gr 1, 2 and 3 rash respectively. pMAPK was not a predictor for response. Using a median score of 20 as the cutoff for pMAPK as positive or negative, negative pMAPK tended to have a longer survival (7.6 mo vs. 5.3 mo, p=0.051). A gr ≥ 2 rash trended towards an association with prolonged survival (12.6 mo vs. 6.4 mo, p=0.099). Conclusions: Elb used as first-line treatment in an unselected population has a response rate and survival similar to first-line chemotherapy. Negative pMAPK may predict for prolonged survival but does not predict response. EGFR mutation and FISH analysis will be available at the meeting. No significant financial relationships to disclose.
Fatal autoimmune hemolytic anemia associated with ibuprofen
Authors: J. B. Guidry
Journal: JAMA (1979)

IBUPROFEN is a phenylproprionate anti-inflammatory agent that has been used for several years for the treatment of a variety of arthritides.<sup>1</sup>Side effects and idiosyncratic reactions have generally occurred less frequently with this agent than with other nonsteroidal anti-inflammatory agents.<sup>2</sup>We report here the occurrence of fatal autoimmune hemolytic anemia coincident with the administration of ibuprofen. <h3>Report of a Case</h3> A 49-year-old man was transferred to the Birmingham, Ala, Veterans Administration Hospital because of an acute illness characterized by fever, abdominal pain, hemolytic anemia, jaundice, renal failure, and shock. He had been hospitalized elsewhere ten days earlier because of left ankle pain and swelling that had been intermittent for several months. Hemogram, renal function, hepatic function, and roentgenograms of the left ankle were normal. He was treated with ibuprofen, 400 mg three times daily by mouth, and oxazepam, 10 mg three times daily by mouth. He was asymptomatic
Radiotherapeutic Approach
Authors: C. C. Wang
Journal: JAMA (1972)

Squamous cell carcinomas arising from various anatomic sites of the hypopharynx and larynx are quite dissimilar from the standpoint of natural history, tumor type, mode of spread, prognosis, and methods of treatment. The hypopharyngeal tumors include lesions of the pyriform sinus, postcricoid area, and posterior pharyngeal wall. The laryngeal tumors are composed of the lesions arising from the supraglottic, glottic, and subglottic regions. Lesions originating from the laryngeal surface and the rim of the epiglottis, aryepiglottic fold, arytenoid, false cord, and laryngeal ventricle are included in the category of supraglottic carcinomas. Both hypopharyngeal and supraglottic carcinomas are characterized by (1) tumors that are both locally aggressive and extensive, owing to the lack of significant symptoms until late stages of the disease; (2) high incidence of regional lymph node metastases, not infrequently bilateral; (3) frequent involvement of the adjacent soft tissue and the cartilage; and (4) unsatisfactory therapeutic results, either by
Access to Health Care
Authors: Henry Greenberg
Journal: Annals of Internal Medicine (1993)

Letters1 February 1993Access to Health CareHenry Greenberg, MDHenry Greenberg, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-3-199302010-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:If the authors of the ACP position paper had been optimistic types, they would have listed excellence first, not third. Although many specifics of proposed health care plans will be questioned, challenged, and changed, the ACP plan must preserve that one characteristic.The American automobile industry lost its excellence and now we pay a terrible price for it. Although we may be able to regain excellence and rebuild markets for automobiles, the ability to restructure excellence in medicine, once lost, will take decades, not years, to regain. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1993Volume 118, Issue 3Page: 232-235KeywordsHealth care ePublished: 15 August 2000 Issue Published: 1 February 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Reply
Authors: Takashi Kokudo, Kiyoshi Hasegawa, Norihiro Kokudo
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. We would like to thank Zhang et al. and Pei et al. for their comments regarding our recently published article.1 As Zhang et al. have mentioned, although a randomized controlled trial would be ideal, our present findings suggest the addition of surgical treatment to the current treatment guidelines as a treatment option for patients with hepatic vein tumor thrombosis (HVTT).2 Concerning the classification of HVTT, because major HVTT generally involves the major hepatic veins (right, middle, and left hepatic veins), the edge of the thrombus as well as the tumor thrombus in the major portal vein are relatively easy to identify (Fig. 1). This classification is simple and has been widely used for more than three decades in Japan as General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Although future validation would be necessary, because no other classification exists to date, our classification seems to be valid and has the ability to stratify the patients' prognosis.3Figure 1: Computed tomographic image showing the tumor thrombus (arrowhead) in the middle hepatic vein. MHV, middle hepatic vein; MT, main tumor.Because the results are based on the database of a nation‐wide survey, a precise surgical technique, including an anterior approach or anatomical resection, was not available. However, 76.5% of the patients with major HVTT required major liver resection for the complete removal of tumor. Therefore, most of the patients are estimated to have undergone anatomical resection not only for survival benefit, but also for technical necessity. Although the early ligation of the portal pedicles and the subsequent clamping of major hepatic veins are considered to be theoretically better given that they avoid dissemination in patients with major HVTT, the impact of the anterior approach in recurrence‐free survival is controversial.4 As we have previously mentioned, because bleeding control during liver transection is considered to be most important, we prioritize the conventional approach.5 Liver resection in patients with HVTT is technically demanding; thus, safety should be prioritized unless reliable evidence of a disadvantage with regard to postoperative recurrence can be demonstrated.
London.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hospital Events Associated With Adverse Events and Substandard Care
Authors: James Schlosser
Journal: JAMA (1991)

<h3>To the Editor.</h3> —The thoughful article by Brennan et al<sup>1</sup>reported data on the distribution of negligent AEs in 52 hospitals in New York. The range of this distribution was 1% to 60% (mean, 25%). With these data collected over 1 year, the authors asserted that this distribution was significantly nonrandom (<i>P</i>&lt;.001). We might easily conceive of a random process that generates samples, with a mean of 25 and a range of 1% to 60%. Only by understanding the processes that generate negligent AEs and by studying rates over time might we determine whether the rates are part of a common cause variation (ie, due to chance alone) or are due to special causes (ie, nonrandom).<sup>2</sup>Park et al<sup>3</sup>illustrated this issue with hospital death rates. Contrary to the assertion by Brennan et al, high outlier hospitals should not "be the focus of greater internal and
HYPNOTISM AGAIN.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HPV Vaccine Slashes Rates of Oral Infection
Journal: Cancer Discovery (2017)

Vaccination against human papillomavirus (HPV) reduces the prevalence of oral infection by an estimated 88% among young adults in the United States, a protection that could help reduce rates of HPV-related oropharyngeal cancers, according to data that will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. However, the population-level benefit will remain low unless more people get vaccinated.
Leadership Program Awards Residents and Fellows
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Authors' reply
Authors: R. G Cumming, R. J Klineberg
Journal: Annals of the Rheumatic Diseases (1994)

Matters arising purchasers might consider "buying" inadequately evaluated therapies, on the same basis that physiotherapy was derided for accepting electrotherapy by ".... giving credence to unscientific hype".' Caveat emptor.I fully endorse the author's call for more research into the efficacy of physiotherapy, and already many of the obstacles that impeded physiotherapy research are being addressed.In a recent letter in the British Journal of Rheumatology5 I explained that through the creation of university departments, the expertise and career structure exists to enable us to advance research in physiotherapy.We are now successfully competing for funding to critically evaluate our treatments, so that we can deliver the most effective treatment to our patients with the optimal use of resources.
Do we have yet another spotted fever?
Authors: J. W. Long
Journal: JAMA (1993)

<h3>To the Editor.</h3> —In June 1992, a 65-year-old white male resident of Talbot County, Maryland, developed an acute febrile rash suggestive of Rocky Mountain spotted fever (RMSF). For 2 days he experienced malaise, sneezing, coughing, and generalized aching. On the third day, he developed fever (38.3°C to 39.7°C [101°F to 103.5°F]) and severe headache. On the fourth day, a generalized macular rash appeared on the trunk, arms, and legs, most intense on the anterior thighs. There was no rash on the scalp, face, palms, or soles. Examination revealed no findings indicative of meningitis, rubella, rubeola, varicella, or infectious mononucleosis. Laboratory studies revealed a white blood cell count of 4.3×10<sup>9</sup>/L, segmented neutrophils of 0.80, and bands of 0.13; 20 other blood analytes were normal. The patient was not aware of any insect bites preceding illness. Doxycycline was started the first day of rash and continued with dosage of 100
Bone Pathology
Authors: Danny Chan
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acta Endocrinologica, Copenhagen
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prolonged hyperamylasemia in diabetic ketoacidosis
Authors: E. van Sonnenberg
Journal: JAMA (1976)

SOMOGYI'S pioneer report on blood diastase, associating diabetic ketoacidosis (DKA) with low serum amylase, has been modified by subsequent studies to the extent that the converse is now commonly accepted to be true. Several reports have repeatedly demonstrated<sup>1,2</sup>—and others subsequently analyzed<sup>3</sup>—the importance of an<i>elevated</i>serum amylase level and its relation to the pancreas in DKA. We report a case with many similarities to the aforementioned, but unique in its prolonged hyper-amylasemia with minimal to no abdominal findings in a patient with DKA and coma, lactic acidosis, hypothermia, and hypotension. <h3>Report of a Case</h3> A 54-year-old nonalcoholic woman, a known diabetic for three years who was taking chlorpropamide and phenformin hydrochloride, awakened dizzy on the morning of admission. She had mild nausea, vomited once, and then became increasingly lethargic over the next six to eight hours, with semistupor and Kussmaul respirations. She had no abdominal pain